Thus, transferrin constitutes both a prognostic and a mechanistic biomarker and an attractive surrogate for therapeutic trials aiming to preserve HNF4α signaling as a tool to prevent the development of liver failure. The gene discussed is HNF4A; the disease is liver failure.